Walter Wahli

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


380 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | ...
 
Increased hepatic gluconeogenesis and type 2 diabetes mellitus.
Barroso E., Jurado-Aguilar J., Wahli W., Palomer X., Vázquez-Carrera M. Trends in endocrinology and metabolism. Peer-reviewed.
PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells.
Zhang M., Barroso E., Peña L., Rada P., Valverde Á.M., Wahli W., Palomer X., Vázquez-Carrera M., 2024/10. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 179 p. 117303. Peer-reviewed.
 
The LIDPAD Mouse Model Captures the Multisystem Interactions and Extrahepatic Complications in MASLD.
Low Z.S., Chua D., Cheng H.S., Tee R., Tan W.R., Ball C., Sahib NBE, Ng S.S., Qu J., Liu Y. et al., 2024/09. Advanced science, 11 (35) pp. e2404326. Peer-reviewed.
PPARs as Key Transcription Regulators at the Crossroads of Metabolism and Inflammation.
Vázquez-Carrera M., Wahli W., 2024/04/18. International journal of molecular sciences, 25 (8). Peer-reviewed.
GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway.
Jurado-Aguilar J., Barroso E., Bernard M., Zhang M., Peyman M., Rada P., Valverde Á.M., Wahli W., Palomer X., Vázquez-Carrera M., 2024/03. Metabolism, 152 p. 155772. Peer-reviewed.
The Opioid Receptor Influences Circadian Rhythms in Human Keratinocytes through the β-Arrestin Pathway.
Bigliardi P., Junnarkar S., Markale C., Lo S., Bigliardi E., Kalyuzhny A., Ong S., Dunn R., Wahli W., Bigliardi-Qi M., 2024/01/25. Cells, 13 (3). Peer-reviewed.
Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ.
Zhang M., Barroso E., Ruart M., Peña L., Peyman M., Aguilar-Recarte D., Montori-Grau M., Rada P., Cugat C., Montironi C. et al., 2023/11. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 167 p. 115623. Peer-reviewed.
Striking a gut-liver balance for the antidiabetic effects of metformin.
Barroso E., Montori-Grau M., Wahli W., Palomer X., Vázquez-Carrera M., 2023/07. Trends in pharmacological sciences, 44 (7) pp. 457-473. Peer-reviewed.
A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects.
Aguilar-Recarte D., Barroso E., Zhang M., Rada P., Pizarro-Delgado J., Peña L., Palomer X., Valverde Á.M., Wahli W., Vázquez-Carrera M., 2023/01. Pharmacological research, 187 p. 106578. Peer-reviewed.
Knocking on GDF15's door for the treatment of type 2 diabetes mellitus.
Aguilar-Recarte D., Barroso E., Palomer X., Wahli W., Vázquez-Carrera M., 2022/11. Trends in endocrinology and metabolism, 33 (11) pp. 741-754. Peer-reviewed.
 
Endothelial-immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease.
Ng C.Y., Lee K.L., Muthiah M.D., Wu K.X., Chioh FWJ, Tan K., Soon GST, Shabbir A., Loo W.M., Low Z.S. et al., 2022/10/06. EMBO reports, 23 (10) pp. e55871. Peer-reviewed.
Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations.
Espinosa-Jiménez T., Busquets O., Cano A., Sánchez-López E., Verdaguer E., Parcerisas A., Olloquequi J., Auladell C., Folch J., Wahli W. et al., 2022/07/11. Frontiers in pharmacology, 13 p. 902047. Peer-reviewed.
ATGL-dependent white adipose tissue lipolysis controls hepatocyte PPARα activity.
Fougerat A., Schoiswohl G., Polizzi A., Régnier M., Wagner C., Smati S., Fougeray T., Lippi Y., Lasserre F., Raho I. et al., 2022/06/07. Cell reports, 39 (10) p. 110910. Peer-reviewed.
PPARs as Key Mediators in the Regulation of Metabolism and Inflammation.
Vázquez-Carrera M., Wahli W., 2022/04/30. International journal of molecular sciences, 23 (9) p. 5025. Peer-reviewed.
The hepatocyte insulin receptor is required to program the liver clock and rhythmic gene expression.
Fougeray T., Polizzi A., Régnier M., Fougerat A., Ellero-Simatos S., Lippi Y., Smati S., Lasserre F., Tramunt B., Huillet M. et al., 2022/04/12. Cell reports, 39 (2) p. 110674. Peer-reviewed.
Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target.
Smati S., Polizzi A., Fougerat A., Ellero-Simatos S., Blum Y., Lippi Y., Régnier M., Laroyenne A., Huillet M., Arif M. et al., 2022/04. Gut, 71 (4) pp. 807-821. Peer-reviewed.
Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor.
Personnaz J., Piccolo E., Dortignac A., Iacovoni J.S., Mariette J., Rocher V., Polizzi A., Batut A., Deleruyelle S., Bourdens L. et al., 2022/03/25. Science advances, 8 (12) pp. eabg9055. Peer-reviewed.
 
Author Correction: EMPReSS: standardized phenotype screens for functional annotation of the mouse genome
Janier Marc, Almadjub Mohammed, Beuf Olivier, Billotey Claire, Bolbos Radu, Canaple Laurence, Chereul Emmanuel, Grenier Denis, Hiba Bassem, Odet Christophe et al., 2022/03. Nature Genetics, 54 (3) pp. 358-360.
 
Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis.
de Sire A., de Sire R., Curci C., Castiglione F., Wahli W., 2022/02/21. Cells, 11 (4) p. 743. Peer-reviewed.
Adipose-Specific PPARα Knockout Mice Have Increased Lipogenesis by PASK-SREBP1 Signaling and a Polarity Shift to Inflammatory Macrophages in White Adipose Tissue.
Hinds T.D., Kipp Z.A., Xu M., Yiannikouris F.B., Morris A.J., Stec D.F., Wahli W., Stec D.E., 2022. Cells, 11 (1) p. 4. Peer-reviewed.
GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK.
Aguilar-Recarte D., Barroso E., Gumà A., Pizarro-Delgado J., Peña L., Ruart M., Palomer X., Wahli W., Vázquez-Carrera M., 2021/08/10. Cell reports, 36 (6) p. 109501. Peer-reviewed.
The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance.
Aguilar-Recarte D., Palomer X., Wahli W., Vázquez-Carrera M., 2021/08/09. International journal of molecular sciences, 22 (16) p. 8555. Peer-reviewed.
Roles of Estrogens in the Healthy and Diseased Oviparous Vertebrate Liver.
Tramunt B., Montagner A., Tan N.S., Gourdy P., Rémignon H., Wahli W., 2021/07/30. Metabolites, 11 (8) p. 502. Peer-reviewed.
 
LRG1 Promotes Metastatic Dissemination of Melanoma through Regulating EGFR/STAT3 Signalling.
Kwan Y.P., Teo MHY, Lim JCW, Tan M.S., Rosellinny G., Wahli W., Wang X., 2021/06/30. Cancers, 13 (13) p. 3279. Peer-reviewed.
PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis.
Cheng H.S., Yip Y.S., Lim EKY, Wahli W., Tan N.S., 2021/04/29. Cancers, 13 (9) p. 2153. Peer-reviewed.
The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice.
Barretto S.A., Lasserre F., Huillet M., Régnier M., Polizzi A., Lippi Y., Fougerat A., Person E., Bruel S., Bétoulières C. et al., 2021/04/20. Microbiome, 9 (1) p. 93. Peer-reviewed.
Invalidation of the Transcriptional Modulator of Lipid Metabolism PPARβ/δ in T Cells Prevents Age-Related Alteration of Body Composition and Loss of Endurance Capacity.
Rousseau A.S., Murdaca J., Le Menn G., Sibille B., Wahli W., Le Garf S., Chinetti G., Neels J.G., Mothe-Satney I., 2021. Frontiers in physiology, 12 p. 587753. Peer-reviewed.
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C., Fougerat A., Ellero-Simatos S., Loiseau N., Guillou H., Gamet-Payrastre L., Wahli W., 2020/12/21. Biomolecules, 10 (12) p. 1702. Peer-reviewed.
Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm.
Duszka K., Wahli W., 2020/11/12. Nutrients, 12 (11) pp. E3476. Peer-reviewed.
PPARs and Microbiota in Skeletal Muscle Health and Wasting.
Manickam R., Duszka K., Wahli W., 2020/10/29. International journal of molecular sciences, 21 (21) pp. E8056. Peer-reviewed.
Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis.
Kirkby N.S., Raouf J., Ahmetaj-Shala B., Liu B., Mazi S.I., Edin M.L., Chambers M.G., Korotkova M., Wang X., Wahli W. et al., 2020/10/01. Cardiovascular research, 116 (12) pp. 1972-1980. Peer-reviewed.
 
Deficiency in fibroblast PPARβ/δ reduces nonmelanoma skin cancers in mice.
Tan MWY, Sng M.K., Cheng H.S., Low Z.S., Leong BJJ, Chua D., Tan EHP, Chan JSK, Yip Y.S., Lee Y.H. et al., 2020/09. Cell death and differentiation, 27 (9) pp. 2668-2680. Peer-reviewed.
Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity.
Duszka K., Gregor A., Guillou H., König J., Wahli W., 2020/07/16. Cells, 9 (7) p. 1708. Peer-reviewed.
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A., Montagner A., Loiseau N., Guillou H., Wahli W., 2020/07/08. Cells, 9 (7). Peer-reviewed.
Investigating the Role of PPARβ/δ in Retinal Vascular Remodeling Using Pparβ/δ-Deficient Mice.
Ho S.Y., Kwan Y.P., Qiu B., Tan A., Murray H.L., Barathi V.A., Tan N.S., Cheung CMG, Wong T.Y., Wahli W. et al., 2020/06/20. International journal of molecular sciences, 21 (12) p. 4403. Peer-reviewed.
Exploring Extracellular Vesicles Biogenesis in Hypothalamic Cells through a Heavy Isotope Pulse/Trace Proteomic Approach.
Tan C.F., Teo H.S., Park J.E., Dutta B., Tse S.W., Leow M.K., Wahli W., Sze S.K., 2020/05/25. Cells, 9 (5) p. 1320.. Peer-reviewed.
Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
Régnier M., Polizzi A., Smati S., Lukowicz C., Fougerat A., Lippi Y., Fouché E., Lasserre F., Naylies C., Bétoulières C. et al., 2020/04/16. Scientific reports, 10 (1) p. 6489. Peer-reviewed.
 
Regulation of hepatokine gene expression in response to fasting and feeding: Influence of PPAR-α and insulin-dependent signalling in hepatocytes.
Smati S., Régnier M., Fougeray T., Polizzi A., Fougerat A., Lasserre F., Lukowicz C., Tramunt B., Guillaume M., Burnol A.F. et al., 2020/04. Diabetes & metabolism, 46 (2) pp. 129-136. Peer-reviewed.
PPARβ/δ Agonism Upregulates Forkhead Box A2 to Reduce Inflammation in C2C12 Myoblasts and in Skeletal Muscle.
Phua WWT, Tan W.R., Yip Y.S., Hew I.D., Wee JWK, Cheng H.S., Leow MKS, Wahli W., Tan N.S., 2020/03/04. International journal of molecular sciences, 21 (5) p. 1747. Peer-reviewed.
 
Collaborative Regulation of LRG1 by TGF-β1 and PPAR-β/δ Modulates Chronic Pressure Overload-Induced Cardiac Fibrosis.
Liu C., Lim S.T., Teo MHY, Tan MSY, Kulkarni M.D., Qiu B., Li A., Lal S., Dos Remedios C.G., Tan N.S. et al., 2019/12. Circulation. Heart failure, 12 (12) pp. e005962. Peer-reviewed.
The Potential of the FSP1cre-Pparb/d<sup>-</sup><sup>/</sup><sup>-</sup> Mouse Model for Studying Juvenile NAFLD.
Chen J., Zhuang Y., Sng M.K., Tan N.S., Wahli W., 2019/10/15. International journal of molecular sciences, 20 (20). Peer-reviewed.
 
The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology.
Oh HYP, Visvalingam V., Wahli W., 2019/09. FASEB journal, 33 (9) pp. 9706-9730. Peer-reviewed.
 
The gut microbiota influences skeletal muscle mass and function in mice.
Lahiri S., Kim H., Garcia-Perez I., Reza M.M., Martin K.A., Kundu P., Cox L.M., Selkrig J., Posma J.M., Zhang H. et al., 2019/07/24. Science translational medicine, 11 (502) pp. eaan5662. Peer-reviewed.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart J.C., Santos R.D., Aguilar-Salinas C., Aikawa M., Al Rasadi K., Amarenco P., Barter P.J., Ceska R., Corsini A., Després J.P. et al., 2019/06/04. Cardiovascular diabetology, 18 (1) p. 71. Peer-reviewed.
 
Hepatic PPARα is critical in the metabolic adaptation to sepsis.
Paumelle R., Haas J.T., Hennuyer N., Baugé E., Deleye Y., Mesotten D., Langouche L., Vanhoutte J., Cudejko C., Wouters K. et al., 2019/05. Journal of hepatology, 70 (5) pp. 963-973. Peer-reviewed.
Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment.
Cheng H.S., Lee JXT, Wahli W., Tan N.S., 2019/03/30. Molecular cancer, 18 (1) p. 51. Peer-reviewed.
Depletion of Gram-Positive Bacteria Impacts Hepatic Biological Functions During the Light Phase.
Oh HYP, Ellero-Simatos S., Manickam R., Tan N.S., Guillou H., Wahli W., 2019/02/14. International journal of molecular sciences, 20 (4). Peer-reviewed.
 
Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes.
Zarei M., Barroso E., Palomer X., Escolà-Gil J.C., Cedó L., Wahli W., Vázquez-Carrera M., 2019. Clinica e investigacion en arteriosclerosis, 31 (3) pp. 111-118. Peer-reviewed.
 
Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?
Fruchart J.C., Santos R.D., Yamashita S., Libby P., International Atherosclerosis Society/R3i Foundation Consensus Panel, 2019. Diabetes & metabolic syndrome, 13 (4) pp. 2723-2725. Peer-reviewed.
 
The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice.
Caillon A., Duszka K., Wahli W., Rohner-Jeanrenaud F., Altirriba J., 2018/10. Metabolism, 87 pp. 13-17. Peer-reviewed.
The Role of PPARβ/δ in Melanoma Metastasis.
Lim JCW, Kwan Y.P., Tan M.S., Teo MHY, Chiba S., Wahli W., Wang X., 2018/09/20. International journal of molecular sciences, 19 (10). Peer-reviewed.
Metronidazole Causes Skeletal Muscle Atrophy and Modulates Muscle Chronometabolism.
Manickam R., Oh HYP, Tan C.K., Paramalingam E., Wahli W., 2018/08/16. International journal of molecular sciences, 19 (8) pp. E2418. Peer-reviewed.
 
Insights into the role of hepatocyte PPARα activity in response to fasting.
Régnier M., Polizzi A., Lippi Y., Fouché E., Michel G., Lukowicz C., Smati S., Marrot A., Lasserre F., Naylies C. et al., 2018/08/15. Molecular and cellular endocrinology, 471 pp. 75-88. Peer-reviewed.
Enteric Microbiota⁻Gut⁻Brain Axis from the Perspective of Nuclear Receptors.
Duszka K., Wahli W., 2018/07/28. International journal of molecular sciences, 19 (8) pp. E2210. Peer-reviewed.
Insights into the Role of PPARβ/δ in NAFLD.
Chen J., Montagner A., Tan N.S., Wahli W., 2018/06/27. International journal of molecular sciences, 19 (7) p. 1893. Peer-reviewed.
ROS release by PPARβ/δ-null fibroblasts reduces tumor load through epithelial antioxidant response.
Tan EHP, Sng M.K., How ISB, Chan JSK, Chen J., Tan C.K., Wahli W., Tan N.S., 2018/04. Oncogene, 37 (15) pp. 2067-2078. Peer-reviewed.
Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway.
Kirkby N.S., Sampaio W., Etelvino G., Alves D.T., Anders K.L., Temponi R., Shala F., Nair A.S., Ahmetaj-Shala B., Jiao J. et al., 2018/02. Hypertension, 71 (2) pp. 297-305. Peer-reviewed.
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
Zarei M., Barroso E., Palomer X., Dai J., Rada P., Quesada-López T., Escolà-Gil J.C., Cedó L., Zali M.R., Molaei M. et al., 2018/02. Molecular metabolism, 8 pp. 117-131. Peer-reviewed.
Peroxisome Proliferator Activated Receptor Gamma Controls Mature Brown Adipocyte Inducibility through Glycerol Kinase.
Lasar D., Rosenwald M., Kiehlmann E., Balaz M., Tall B., Opitz L., Lidell M.E., Zamboni N., Krznar P., Sun W. et al., 2018/01/16. Cell reports, 22 (3) pp. 760-773. Peer-reviewed.
Complementary intestinal mucosa and microbiota responses to caloric restriction.
Duszka K., Ellero-Simatos S., Ow G.S., Defernez M., Paramalingam E., Tett A., Ying S., König J., Narbad A., Kuznetsov V.A. et al., 2018. Scientific Reports, 8 (1) p. 11338. Peer-reviewed.
Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression.
Sng M.K., Chan JSK, Teo Z., Phua T., Tan EHP, Wee JWK, Koh NJN, Tan C.K., Chen J.P., Pal M. et al., 2018. Cell discovery, 4 p. 15. Peer-reviewed.
PPARγ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium.
Duszka K., Oresic M., Le May C., König J., Wahli W., 2017/11/28. International journal of molecular sciences, 18 (12) pp. E2559. Peer-reviewed.
A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response.
Iroz A., Montagner A., Benhamed F., Levavasseur F., Polizzi A., Anthony E., Régnier M., Fouché E., Lukowicz C., Cauzac M. et al., 2017/10/10. Cell reports, 21 (2) pp. 403-416. Peer-reviewed.
 
Roles of Peroxisome Proliferator-Activated Receptor β/δ in skeletal muscle physiology.
Manickam R., Wahli W., 2017. Biochimie, 136 pp. 42-48. Peer-reviewed.
 
Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
Tan C.K., Zhuang Y., Wahli W., 2017. Expert Opinion on Therapeutic Targets, 21 (3) pp. 333-348. Peer-reviewed.
 
High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.
Tomas J., Mulet C., Saffarian A., Cavin J.B., Ducroc R., Regnault B., Kun Tan C., Duszka K., Burcelin R., Wahli W. et al., 2016/10/04. Proceedings of the National Academy of Sciences of the United States of America, 113 (40) pp. E5934-E5943. Peer-reviewed.
 
Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency.
Zarei M., Barroso E., Leiva R., Barniol-Xicota M., Pujol E., Escolano C., Vázquez S., Palomer X., Pardo V., González-Rodríguez Á. et al., 2016/10. Diabetes, 65 (10) pp. 3185-3199. Peer-reviewed.
 
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ.
Tan N.S., Vázquez-Carrera M., Montagner A., Sng M.K., Guillou H., Wahli W., 2016/10. Progress in lipid research, 64 pp. 98-122.
Hepatic Fasting-Induced PPARα Activity Does Not Depend on Essential Fatty Acids.
Polizzi A., Fouché E., Ducheix S., Lasserre F., Marmugi A.P., Mselli-Lakhal L., Loiseau N., Wahli W., Guillou H., Montagner A., 2016/04/24. International journal of molecular sciences, 17 (10) p. 1624. Peer-reviewed.
Hepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals.
Montagner A., Korecka A., Polizzi A., Lippi Y., Blum Y., Canlet C., Tremblay-Franco M., Gautier-Stein A., Burcelin R., Yen Y.C. et al., 2016/02/16. Scientific reports, 6 p. 20127. Peer-reviewed.
 
A trilogy of glucocorticoid receptor actions.
Tan C.K., Wahli W., 2016. Proceedings of the National Academy of Sciences of the United States of America, 113 (5) pp. 1115-1117.
Every day I dream ...&quot; An interview with the Rwandan Health Minister.
Suter P.M., Wahli W., 2016. Swiss Medical Weekly, 146 pp. w14316.
Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism.
Rando G., Tan C.K., Khaled N., Montagner A., Leuenberger N., Bertrand-Michel J., Paramalingam E., Guillou H., Wahli W., 2016. Elife, 5 pp. e28536. Peer-reviewed.
Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction.
Duszka K., Picard A., Ellero-Simatos S., Chen J., Defernez M., Paramalingam E., Pigram A., Vanoaica L., Canlet C., Parini P. et al., 2016. Scientific Reports, 6 p. 36937. Peer-reviewed.
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A., Polizzi A., Fouché E., Ducheix S., Lippi Y., Lasserre F., Barquissau V., Régnier M., Lukowicz C., Benhamed F. et al., 2016. Gut, 65 (7) pp. 1202-1214. Peer-reviewed.
 
PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation
Barroso Emma, Rodríguez-Rodríguez Rosalía, Chacón Matilde R., Maymó-Masip Elsa, Ferrer Laura, Salvadó Laia, Salmerón Emilio, Wabistch Martin, Palomer Xavier, Vendrell Joan et al., 2015/05. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1852 (5) pp. 1049-1058. Peer-reviewed.
Authorship in scientific publications: analysis and recommendations.
Scientific Integrity Committee of Swiss Academies of Arts And Sciences, Hess C.W., Brückner C., Kaiser T., Mauron A., Wahli W., Wenzel U.J., Salathé M., 2015. Swiss medical weekly, 145 pp. w14108. Peer-reviewed.
 
Inactivation of PPARβ/δ adversely affects satellite cells and reduces postnatal myogenesis.
Chandrashekar P., Manickam R., Ge X., Bonala S., McFarlane C., Sharma M., Wahli W., Kambadur R., 2015. American Journal of Physiology. Endocrinology and Metabolism, 309 (2) pp. E122-E131.
 
Nuclear receptor peroxisome proliferator activated receptor (PPAR) beta/delta in skin wound healing and cancer
Montagner A., Wahli W., Tan N.S., 2015. European Journal of Dermatology, 25 (Suppl 1) pp. 4-11.
 
PPAR-β/δ activation promotes phospholipid transfer protein expression.
Chehaibi K., Cedó L., Metso J., Palomer X., Santos D., Quesada H., Naceur Slimane M., Wahli W., Julve J., Vázquez-Carrera M. et al., 2015. Biochemical Pharmacology, 94 (2) pp. 101-108.
PPARα is Required for PPARδ action in regulation of body weight and hepatic steatosis in mice.
Garbacz W.G., Huang J.T., Higgins L.G., Wahli W., Palmer C.N., 2015. PPAR Research, 2015 p. 927057.
The coactivator PGC-1α regulates mouse skeletal muscle oxidative metabolism independently of the nuclear receptor PPARβ/δ in sedentary mice fed a regular chow diet
Pérez-Schindler J., Svensson K., Vargas-Fernández E., Santos G., Wahli W., Handschin C., 2015. Diabetologia, 57 (11) pp. 2405-2412. Peer-reviewed.
Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway.
Kundu P., Ling T.W., Korecka A., Li Y., D'Arienzo R., Bunte R.M., Berger T., Arulampalam V., Chambon P., Mak T.W. et al., 2014. PLoS Pathogens, 10 (1) pp. e1003887.
 
Myostatin augments muscle-specific ring finger protein-1 expression through an NF-kB independent mechanism in SMAD3 null muscle.
Sriram S., Subramanian S., Juvvuna P.K., Ge X., Lokireddy S., McFarlane C.D., Wahli W., Kambadur R., Sharma M., 2014. Molecular Endocrinology, 28 (3) pp. 317-330.
 
PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells.
Palomer X., Capdevila-Busquets E., Botteri G., Salvadó L., Barroso E., Davidson M.M., Michalik L., Wahli W., Vázquez-Carrera M., 2014. International Journal of Cardiology, 174 (1) pp. 110-118.
 
PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism.
Salvadó L., Barroso E., Gómez-Foix A.M., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2014. Diabetologia, 57 (10) pp. 2126-2135. Peer-reviewed.
Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer.
Montagner A., Delgado M.B., Tallichet-Blanc C., Chan J.S., Sng M.K., Mottaz H., Degueurce G., Lippi Y., Moret C., Baruchet M. et al., 2014. EMBO Molecular Medicine, 6 (1) pp. 80-98.
The emerging role of Nrf2 in dermatotoxicology.
Tan N.S., Wahli W., 2014. EMBO Molecular Medicine, 6 (4) pp. 431-433.
Contributions of peroxisome proliferator-activated receptor β/δ to skin health and disease
Montagner A., Wahli W., 2013. Biomolecular Concepts, 4 (1) pp. 53-64.
PPARβ Interprets a Chromatin Signature of Pluripotency to Promote Embryonic Differentiation at Gastrulation.
Rotman N., Guex N., Gouranton E., Wahli W., 2013. PLoS One, 8 (12) pp. e83300.
 
Role of the circadian clock gene Per2 in adaptation to cold temperature.
Chappuis S., Ripperger J.A., Schnell A., Rando G., Jud C., Wahli W., Albrecht U., 2013. Molecular Metabolism, 2 (3) pp. 184-193.
 
Studying Wound Repair in the Mouse.
Tan N.S., Wahli W., 2013. Current Protocols In Mouse Biology, 3 (3) pp. 171-185. Peer-reviewed.
 
Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice.
Barroso E., del Valle J., Porquet D., Vieira Santos A.M., Salvadó L., Rodríguez-Rodríguez R., Gutiérrez P., Anglada-Huguet M., Alberch J., Camins A. et al., 2013. Biochimica et Biophysica Acta. Molecular Basis of Disease, 1832 (8) pp. 1241-1248. Peer-reviewed.
The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids.
Ding J., Loizides-Mangold U., Rando G., Zoete V., Michielin O., Reddy J.K., Wahli W., Riezman H., Thorens B., 2013. Cell Reports, 5 (1) pp. 248-258.
GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.
Kostadinova R., Montagner A., Gouranton E., Fleury S., Guillou H., Dombrowicz D., Desreumaux P., Wahli W., 2012. Cell and Bioscience, 2 (1) p. 34.
 
Lack of Smad3 signaling leads to impaired skeletal muscle regeneration.
Ge X., Vajjala A., McFarlane C., Wahli W., Sharma M., Kambadur R., 2012. American Journal of Physiology. Endocrinology and Metabolism, 303 (1) pp. E90-102.
 
PPARs at the crossroads of lipid signaling and inflammation.
Wahli W., Michalik L., 2012. Trends in Endocrinology and Metabolism, 23 (7) pp. 351-363.
 
PPARβ/δ affects pancreatic β cell mass and insulin secretion in mice.
Iglesias J., Barg S., Vallois D., Lahiri S., Roger C., Yessoufou A., Pradevand S., McDonald A., Bonal C., Reimann F. et al., 2012. Journal of Clinical Investigation, 122 (11) pp. 4105-4117.
The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells.
Woldt E., Terrand J., Mlih M., Matz R.L., Bruban V., Coudane F., Foppolo S., El Asmar Z., Chollet M.E., Ninio E. et al., 2012. Nature Communications, 3 (1077) pp. 1-10. Peer-reviewed.
 
The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Serrano-Marco L., Barroso E., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2012. Diabetologia, 55 (3) pp. 743-751.
Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.
Serrano-Marco L., Rodríguez-Calvo R., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2011. Diabetes, 60 (7) pp. 1990-1999.
Beneficial effects of combinatorial micronutrition on body fat and atherosclerosis in mice.
El Kochairi I., Montagner A., Rando G., Lohmann C., Matter C.M., Wahli W., 2011. Cardiovascular Research, 91 (4) pp. 732-741. Peer-reviewed.
 
Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia.
Kulozik P., Jones A., Mattijssen F., Rose A.J., Reimann A., Strzoda D., Kleinsorg S., Raupp C., Kleinschmidt J., Müller-Decker K. et al., 2011. Cell Metabolism, 13 (4) pp. 389-400.
 
La nutrigénomique dans votre assiette
Wahli W., Constantin N, 2011. 212, De Boeck.
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats.
Deblon N., Veyrat-Durebex C., Bourgoin L., Caillon A., Bussier A.L., Petrosino S., Piscitelli F., Legros J.J., Geenen V., Foti M. et al., 2011. PLoS One, 6 (9) pp. e25565.
 
New insights into the role of PPARs.
Montagner A., Rando G., Degueurce G., Leuenberger N., Michalik L., Wahli W., 2011. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 85 (5) pp. 235-243. Peer-reviewed.
 
PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.
Alvarez-Guardia D., Palomer X., Coll T., Serrano L., Rodríguez-Calvo R., Davidson M.M., Merlos M., El Kochairi I., Michalik L., Wahli W. et al., 2011. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1811 (2) pp. 59-67. Peer-reviewed.
Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPAR alpha) activity.
Gachon F., Leuenberger N., Claudel T., Gos P., Jouffe C., Fleury Olela F., de Mollerat du Jeu X., Wahli W., Schibler U., 2011. Proceedings of the National Academy of Sciences of the United States of America, 108 (12) pp. 4794-4799. Peer-reviewed.
 
Sex differences in nuclear receptor-regulated liver metabolic pathways.
Rando G., Wahli W., 2011. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1812 (8) pp. 964-973. Peer-reviewed.
Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet.
Tan C.K., Leuenberger N., Tan M.J., Yan Y.W., Chen Y., Kambadur R., Wahli W., Tan N.S., 2011. Diabetes, 60 (2) pp. 464-476. Peer-reviewed.
 
Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts.
Ge X., McFarlane C., Vajjala A., Lokireddy S., Ng Z.H., Tan C.K., Tan N.S., Wahli W., Sharma M., Kambadur R., 2011. Cell Research, 21 (11) pp. 1591-1604.
The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice.
Hensler M., Bardova K., Jilkova Z.M., Wahli W., Meztger D., Chambon P., Kopecky J., Flachs P., 2011. Lipids in Health and Disease, 10 (1) p. 128.
Peroxisome proliferator-activated receptor β/δ: a master regulator of metabolic pathways in skeletal muscle.
Lahiri S., Wahli W., 2010/12/01. Hormone molecular biology and clinical investigation, 4 (2) pp. 565-573. Peer-reviewed.
 
Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes.
Vegiopoulos A., Müller-Decker K., Strzoda D., Schmitt I., Chichelnitskiy E., Ostertag A., Berriel Diaz M., Rozman J., Hrabe de Angelis M., Nüsing R.M. et al., 2010. Science, 328 (5982) pp. 1158-1161.
EuroPhenome: a repository for high-throughput mouse phenotyping data.
Morgan H., Beck T., Blake A., Gates H., Adams N., Debouzy G., Leblanc S., Lengger C., Maier H., Melvin D. et al., 2010/01. Nucleic acids research, 38 (Database issue) pp. D577-85. Peer-reviewed.
Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
Yessoufou A., Wahli W., 2010. Swiss Medical Weekly, 140 pp. w13071.
 
PPAR modulation of kinase-linked receptor signaling in physiology and disease.
Rotman N., Wahli W., 2010. Physiology, 25 (3) pp. 176-185.
 
PPARα, a key regulator of hepatic energy homeostasis in health and disease
Leuenberger N., Wahli W., 2010. pp. 305-315 dans Dufour J.F., Clavien P.A. (eds.) Signaling Pathways in Liver Diseases, Springer-Verlag.
A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages.
Demers A., Caron V., Rodrigue-Way A., Wahli W., Ong H., Tremblay A., 2009. Plos One, 4 (11) pp. e7728. Peer-reviewed.
 
Activation of PPAR delta Regulates Ywhae (Encoding 14-3-3 epsilon Protein), a Gene Required for Ventricular Morphogenesis
Brunelli L., Cieslik K.A., Michalik L., Wahli W., Yost H.J., 2009. pp. E15-E15 dans Basic Cardiovascular Sciences Conference 2009, Circulation Research. Peer-reviewed.
 
Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets.
Lohmann C., Schäfer N., von Lukowicz T., Sokrates Stein M.A., Borén J., Rütti S., Wahli W., Donath M.Y., Lüscher T.F., Matter C.M., 2009. Atherosclerosis, 207 (2) pp. 360-367. Peer-reviewed.
 
Fatty acid synthesis and PPARalpha hand in hand.
Rotman N., Wahli W., 2009. Chemistry and Biology, 16 (8) pp. 801-802.
 
Nutrigenomik, ein neuer Weg zur Gesundheit
Wahli W., Constantin N., 2009. Swiss Medical Forum = Forum Médical Suisse, 9 (11) pp. 224-227.
 
Nutrigenomik, eine medizinische, soziale und ökonomische Herausforderung
Wahli W., Constantin N., 2009. Swiss Medical Forum = Forum Médical Suisse, 9 (12) pp. 242-245.
 
Parts of the bothrops moojeni snake venom activated lipid synthesis and PPARA, B, Gamma 2 in transiently transfected sz95 sebocytes
Schagen S. K., Perchuc A.-.M., Voegeli R., Imfeld D., Schreier T., Michalik L., Wahli W., Zouboulis C. C., 2009. Journal der Deutschen Dermatologischen Gesellschaft, 7 pp. 152-153. Peer-reviewed.
Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.
Chong H.C., Tan M.J., Philippe V., Tan S.H., Tan C.K., Ku C.W., Goh Y.Y., Wahli W., Michalik L., Tan N.S., 2009. Journal of Cell Biology, 184 (6) pp. 817-831. Peer-reviewed.
 
Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice.
Leuenberger N., Pradervand S., Wahli W., 2009. Journal of Clinical Investigation, 119 (10) pp. 3138-3148. Peer-reviewed.
 
A gut feeling of the PXR, PPAR and NF-kappaB connection.
Wahli W., 2008. Journal of Internal Medicine, 263 (6) pp. 613-619.
Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.
Rodríguez-Calvo R., Serrano L., Coll T., Moullan N., Sánchez R.M., Merlos M., Palomer X., Laguna J.C., Michalik L., Wahli W. et al., 2008. Diabetes, 57 (8) pp. 2149-2157. Peer-reviewed.
Loss of egg yolk genes in mammals and the origin of lactation and placentation
Brawand D., Wahli W., Kaessmann H., 2008. PLoS Biology, 6 (3) pp. e63. Peer-reviewed.
 
Nutrition, gestion de l'énergie et surpoids: que font donc nos gènes
Wahli W., 2008. Nouveaux cahiers, 3 pp. 44-78.
 
Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer.
Jahoor A., Patel R., Bryan A., Do C., Krier J., Watters C., Wahli W., Li G., Williams S.C., Rumbaugh K.P., 2008. Journal of Bacteriology, 190 (13) pp. 4408-4415. Peer-reviewed.
 
PPAR disruption: Cellular mechanisms and physiological consequences
Rotman N., Haftek-Terreau Z., Luecke S., Feige J., Gelman L., Desvergne B., Wahli W., 2008. CHIMIA, 62 (5) pp. 340-344. Peer-reviewed.
 
PPAR gamma: ally and foe in bone metabolism.
Wahli W., 2008. Cell Metabolism, 7 (3) pp. 188-190.
PPARs Mediate Lipid Signaling in Inflammation and Cancer.
Michalik L., Wahli W., 2008. PPAR Research, 2008 p. 134059. Peer-reviewed.
 
Tissue repair and cancer control through PPARs and their coregulators
Michalik L., Wahli W., 2008. pp. 409-440 dans Kumar B., O'Malley R. W. (eds.) Nuclear Receptor Coregulators in Human Diseases chap. 13, World Scientific Publishing.
 
Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma.
Anghel S.I., Bedu E., Vivier C.D., Descombes P., Desvergne B., Wahli W., 2007. Journal of Biological Chemistry, 282 (41) pp. 29946-29957. Peer-reviewed.
 
Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells.
Tudor C., Feige J.N., Pingali H., Lohray V.B., Wahli W., Desvergne B., Engelborghs Y., Gelman L., 2007. Journal of Biological Chemistry, 282 (7) pp. 4417-4426. Peer-reviewed.
 
Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior.
Michalik L., Zoete V., Krey G., Grosdidier A., Gelman L., Chodanowski P., Feige J.N., Desvergne B., Wahli W., Michielin O., 2007. Journal of Biological Chemistry, 282 (13) pp. 9666-9677. Peer-reviewed.
 
Fat poetry: a kingdom for PPAR gamma.
Anghel S.I., Wahli W., 2007. Cell Research, 17 (6) pp. 486-511. Peer-reviewed.
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
Mandard S., Stienstra R., Escher P., Tan N.S., Kim I., Gonzalez F.J., Wahli W., Desvergne B., Müller M., Kersten S., 2007. Cellular and Molecular Life Sciences, 64 (9) pp. 1145-1157. Peer-reviewed.
 
Guiding ligands to nuclear receptors.
Michalik L., Wahli W., 2007. Cell, 129 (4) pp. 649-651. Peer-reviewed.
 
IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.
Berry A., Balard P., Coste A., Olagnier D., Lagane C., Authier H., Benoit-Vical F., Lepert J.C., Séguéla J.P., Magnaval J.F. et al., 2007. European Journal of Immunology, 37 (6) pp. 1642-1652. Peer-reviewed.
 
Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes.
Indra A.K., Castaneda E., Antal M.C., Jiang M., Messaddeq N., Meng X., Loehr C.V., Gariglio P., Kato S., Wahli W. et al., 2007. Journal of Investigative Dermatology, 127 (5) pp. 1250-1260. Peer-reviewed.
 
Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease.
Michalik L., Wahli W., 2007. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1771 (8) pp. 991-998. Peer-reviewed.
 
Roles of the peroxisome proliferators-activated receptor (PPAR) alpha and beta/delta in skin wound healing
Michalik L., Wahli W., 2007., Proceedings of the Esteve Foundation Symposium 12, held between 4 and 7 October 2006, S'Agaro (Girona), Spain pp. 45-52 dans Werner S. (eds.) Molecular Biology and Pharmacology of tissue Repair, International Congress Series, Elsevier.
 
Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success.
Wang H., Xie H., Sun X., Tranguch S., Zhang H., Jia X., Wang D., Das S.K., Desvergne B., Wahli W. et al., 2007. Journal of Biological Chemistry, 282 (52) pp. 37770-37782. Peer-reviewed.
 
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.
Feige J.N., Gelman L., Rossi D., Zoete V., Métivier R., Tudor C., Anghel S.I., Grosdidier A., Lathion C., Engelborghs Y. et al., 2007. Journal of Biological Chemistry, 282 (26) pp. 19152-19166. Peer-reviewed.
 
The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver.
Stienstra R., Mandard S., Tan N.S., Wahli W., Trautwein C., Richardson T.A., Lichtenauer-Kaligis E., Kersten S., Müller M., 2007. Journal of Hepatology, 46 (5) pp. 869-877. Peer-reviewed.
 
The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.
Tan N.S., Icre G., Montagner A., Bordier-ten-Heggeler B., Wahli W., Michalik L., 2007. Molecular and Cellular Biology, 27 (20) pp. 7161-7175. Peer-reviewed.
 
A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway.
Avallone R., Demers A., Rodrigue-Way A., Bujold K., Harb D., Anghel S., Wahli W., Marleau S., Ong H., Tremblay A., 2006. Molecular Endocrinology, 20 (12) pp. 3165-3178. Peer-reviewed.
 
Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression.
Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., DuBois R.N., 2006. Proceedings of the National Academy of Sciences of the United States of America, 103 (50) pp. 19069-19074. Peer-reviewed.
 
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta.
Nadra K., Anghel S.I., Joye E., Tan N.S., Basu-Modak S., Trono D., Wahli W., Desvergne B., 2006. Molecular and Cellular Biology, 26 (8) pp. 3266-3281. Peer-reviewed.
 
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W., 2006. Progress in Lipid Research, 45 (2) pp. 120-159. Peer-reviewed.
 
Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis.
Icre G., Wahli W., Michalik L., 2006. Journal of Investigative Dermatology, 11 (1) pp. 30-35. Peer-reviewed.
Integrating nuclear receptor mobility in models of gene regulation.
Gelman L., Feige J.N., Tudor C., Engelborghs Y., Wahli W., Desvergne B., 2006. Nuclear Receptor Signaling, 4 pp. e010. Peer-reviewed.
 
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S. et al., 2006. Pharmacological Reviews, 58 (4) pp. 726-741. Peer-reviewed.
 
Involvement of PPAR nuclear receptors in tissue injury and wound repair.
Michalik L., Wahli W., 2006. Journal of Clinical Investigation, 116 (3) pp. 598-606. Peer-reviewed.
 
Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain.
Knauf C., Rieusset J., Foretz M., Cani P.D., Uldry M., Hosokawa M., Martinez E., Bringart M., Waget A., Kersten S. et al., 2006. Endocrinology, 147 (9) pp. 4067-4078. Peer-reviewed.
 
PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes.
Schuler M., Ali F., Chambon C., Duteil D., Bornert J.M., Tardivel A., Desvergne B., Wahli W., Chambon P., Metzger D., 2006. Cell Metabolism, 4 (5) pp. 407-414. Peer-reviewed.
 
Physiological ligands of PPARs in inflammation and lipid homeostasis
Lathion C., Michalik L., Wahli W., 2006. Future Lipidology, 1 (2) pp. 191-201. Peer-reviewed.
 
PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway.
Varnat F., Heggeler B.B., Grisel P., Boucard N., Corthésy-Theulaz I., Wahli W., Desvergne B., 2006. Gastroenterology, 131 (2) pp. 538-553. Peer-reviewed.
 
PPARs and colon cancers : A curse or a cure ?
Michalik L., Wahli W., 2006. pp. 145-161 dans Bamba H., Ota S. (eds.) Recent Advances in Gastrointestinal Carcinogenesis, Transworld Research Network.
 
PPARs in fetal and early postnatal development
Rotman N., Michalik L., Desvergne B., Wahli W., 2006. pp. 33-64 dans Tanejah R. (eds.) Nuclear receptors in development chap. 2, Elsevier.
 
PPARs: lipid sensors that regulate cell differentiation processes
Varnat F., Michalik L., Desvergne B., Wahli W., 2006. pp. 117-131 dans Brigelius-Flohé R., Joost H.G. (eds.) Nutritional genomics : impact on health and disease chap. 7, Wiley-VCH.
 
Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock.
Canaple L., Rambaud J., Dkhissi-Benyahya O., Rayet B., Tan N.S., Michalik L., Delaunay F., Wahli W., Laudet V., 2006. Molecular Endocrinology, 20 (8) pp. 1715-1727. Peer-reviewed.
 
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.
Ali F.Y., Egan K., FitzGerald G.A., Desvergne B., Wahli W., Bishop-Bailey D., Warner T.D., Mitchell J.A., 2006. American Journal of Respiratory Cell and Molecular Biology, 34 (2) pp. 242-246. Peer-reviewed.
 
The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity.
Mandard S., Zandbergen F., van Straten E., Wahli W., Kuipers F., Müller M., Kersten S., 2006. Journal of Biological Chemistry, 281 (2) pp. 934-944. Peer-reviewed.
 
Transcriptional regulation of metabolism.
Desvergne B., Michalik L., Wahli W., 2006. Physiological Reviews, 86 (2) pp. 465-514. Peer-reviewed.
 
Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice.
Skrtic S., Carlsson L., Ljungberg A., Lindén D., Michalik L., Wahli W., Oscarsson J., 2005. Liver International, 25 (1) pp. 33-40. Peer-reviewed.
 
Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice.
Yang Z.Z., Tschopp O., Di-Poï N., Bruder E., Baudry A., Dümmler B., Wahli W., Hemmings B.A., 2005. Molecular and Cellular Biology, 25 (23) pp. 10407-10418. Peer-reviewed.
 
EMPReSS: standardised phenotype screens for functional annotation of the mouse genome
Eumorphia_Consortium, Wahli W., Delgado MB., Desvergne B., Michalik L., Bedu E., 2005. Nature Genetics, 37 (11) p. 1155. Peer-reviewed.
 
Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development.
Di-Poï N., Ng C.Y., Tan N.S., Yang Z., Hemmings B.A., Desvergne B., Michalik L., Wahli W., 2005. Molecular and Cellular Biology, 25 (5) pp. 1696-1712. Peer-reviewed.
 
Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand.
Feige J.N., Gelman L., Tudor C., Engelborghs Y., Wahli W., Desvergne B., 2005. Journal of Biological Chemistry, 280 (18) pp. 17880-17890. Peer-reviewed.
 
Functional role of RXRs and PPARgamma in mature adipocytes.
Metzger D., Imai T., Jiang M., Takukawa R., Desvergne B., Wahli W., Chambon P., 2005. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 73 (1) pp. 51-58. Peer-reviewed.
 
Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Journal of Biological Chemistry, 280 (18) pp. 18163-18170. Peer-reviewed.
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.
Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., Metzger D., Wahli W., Desvergne B., Naccari G.C. et al., 2005. Journal of Experimental Medicine, 201 (8) pp. 1205-1215. Peer-reviewed.
 
Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
Gelman L., Michalik L., Desvergne B., Wahli W., 2005. Current Opinion in Cell Biology, 17 (2) pp. 216-222. Peer-reviewed.
 
Microsomal triglyceride transfer protein promotes the secretion of Xenopus laevis vitellogenin A1.
Sellers J.A., Hou L., Schoenberg D.R., Batistuzzo de Medeiros S.R., Wahli W., Shelness G.S., 2005. Journal of Biological Chemistry, 280 (14) pp. 13902-13905. Peer-reviewed.
 
Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Journal of Steroid Biochemistry and Molecular Biology, 93 (2-5) pp. 99-105. Peer-reviewed.
 
Nutrigenomics and nutrigenetics: the emerging faces of nutrition.
Mutch D.M., Wahli W., Williamson G., 2005. FASEB journal, 19 (12) pp. 1602-1616. Peer-reviewed.
 
Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation.
Gremlich S., Nolan C., Roduit R., Burcelin R., Peyot M.L., Delghingaro-Augusto V., Desvergne B., Michalik L., Prentki M., Wahli W., 2005. Endocrinology, 146 (1) pp. 375-382. Peer-reviewed.
 
Peroxisome proliferator activated receptors
Genolet R., Michalik L., Wahli W., 2005. pp. 267-280 dans Dufour J.F., Clavien P.A., Trautwein C., Graf R. (eds.) Signaling pathways in liver diseases, Springer.
Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.
Planavila A., Rodríguez-Calvo R., Jové M., Michalik L., Wahli W., Laguna J.C., Vázquez-Carrera M., 2005. Cardiovascular Research, 65 (4) pp. 832-841. Peer-reviewed.
 
Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
Bedu E., Wahli W., Desvergne B., 2005. Expert Opinion On Therapeutic Targets, 9 (4) pp. 861-873. Peer-reviewed.
 
Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure.
Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., Heudes D., Wahli W., Desvergne B., Baud L., 2005. Journal of the American Society of Nephrology, 16 (8) pp. 2395-2402. Peer-reviewed.
 
PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs.
Feige J.N., Sage D., Wahli W., Desvergne B., Gelman L., 2005. Microscopy Research and Technique, 68 (1) pp. 51-58. Peer-reviewed.
 
PPARs in diseases: control mechanisms of inflammation.
Kostadinova R., Wahli W., Michalik L., 2005. Current Medicinal Chemistry, 12 (25) pp. 2995-3009. Peer-reviewed.
 
Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha.
Genolet R., Kersten S., Braissant O., Mandard S., Tan N.S., Bucher P., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (25) pp. 24143-24152. Peer-reviewed.
 
Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity.
Debril M.B., Dubuquoy L., Feige J.N., Wahli W., Desvergne B., Auwerx J., Gelman L., 2005. Journal of Molecular Endocrinology, 35 (3) pp. 503-517. Peer-reviewed.
 
Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing.
Michalik L., Feige J.N., Gelman L., Pedrazzini T., Keller H., Desvergne B., Wahli W., 2005. Molecular Endocrinology, 19 (9) pp. 2335-2348. Peer-reviewed.
 
The G0/G1 switch gene 2 is a novel PPAR target gene.
Zandbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoe T., Rojas-Caro S., Madore S., Wahli W., Tafuri S. et al., 2005. Biochemical Journal, 392 (Pt 2) pp. 313-324. Peer-reviewed.
 
Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.
Di-Poï N., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (46) pp. 38700-38710. Peer-reviewed.
 
Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action.
Rieusset J., Seydoux J., Anghel S.I., Escher P., Michalik L., Soon Tan N., Metzger D., Chambon P., Wahli W., Desvergne B., 2004. Molecular Endocrinology, 18 (10) pp. 2363-2377. Peer-reviewed.
 
Be fit or be sick: peroxisome proliferator-activated receptors are down the road.
Desvergne B., Michalik L., Wahli W., 2004. Molecular Endocrinology, 18 (6) pp. 1321-1332. Peer-reviewed.
 
Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing.
Tan N.S., Michalik L., Di-Poï N., Desvergne B., Wahli W., 2004. Biochemical Society Transactions, 32 (Pt 1) pp. 97-102. Peer-reviewed.
 
Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.
Tan N.S., Michalik L., Di-Poï N., Ng C.Y., Mermod N., Roberts A.B., Desvergne B., Wahli W., 2004. EMBO Journal, 23 (21) pp. 4211-4221. Peer-reviewed.
Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.
Di-Poï N., Michalik L., Desvergne B., Wahli W., 2004. Lipids, 39 (11) pp. 1093-1099. Peer-reviewed.
 
Impaired expression of NADH dehydrogenase subunit 1 and PPARgamma coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone.
Jové M., Salla J., Planavila A., Cabrero A., Michalik L., Wahli W., Laguna J.C., Vázquez-Carrera M., 2004. Journal of Lipid Research, 45 (1) pp. 113-123. Peer-reviewed.
 
In vivo activation of PPAR target genes by RXR homodimers.
Ijpenberg A., Tan N.S., Gelman L., Kersten S., Seydoux J., Xu J., Metzger D., Canaple L., Chambon P., Wahli W. et al., 2004. EMBO Journal, 23 (10) pp. 2083-2091. Peer-reviewed.
 
Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha.
Sanguino E., Ramón M., Michalik L., Wahli W., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C., 2004. Biochemical Pharmacology, 67 (1) pp. 157-166. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University